Biocon, Bristol-Myers in deal for oral insulin drug

MUMBAI Fri Nov 16, 2012 10:49am IST

Related Topics

Stocks

   

MUMBAI (Reuters) - Biocon Ltd, India's top-listed biotechnology company, said it signed an agreement with Bristol-Myers Squibb Co under which the U.S. drugmaker will have the option to get the worldwide license to its oral insulin drug program.

Bristol Myers can choose to assume full responsibility for the development of the drug IN-105, if its mid-stage trial is successful.

Biocon, which has been looking to partner the drug for nearly two years, said it would receive a license fee as well as milestone payments and royalties based on commercial sales of the drug outside India. It will retain the rights to IN-105 in India.

Financial terms of the deal were not available.

Currently, there are no insulin tablets available and patients with diabetes who need insulin -- a naturally occurring protein that controls blood sugar -- must inject it.

Earlier this year, Pfizer scrapped a deal to sell injectable insulin products made by Biocon.

Biocon shares, which rose more than 4 percent in the previous session, were down 0.4 percent on Friday, while the broader market was up 0.3 percent.

(Reporting by Aradhana Aravindan; Editing by G.Ram Mohan)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Ebola Outbreak

REUTERS SHOWCASE

Fighting Hunger

Fighting Hunger

Hunger easing globally but 1 in 9 people undernourished: report.  Full Article 

Whooping Cough

Whooping Cough

Parents' whooping cough vaccines may protect babies.  Full Article 

Leg Pain

Leg Pain

Chiropractic care may ease back-related leg pain.  Full Article 

Fitness Tip

Fitness Tip

To make the most of a workout, experts say set the proper pace.  Full Article 

E-cigarettes

E-cigarettes

As Big Tobacco takes up e-cigarettes, investors look ahead.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage